India Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India's Oral Anti-Diabetic Drug Market is Segmented Into Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-d2 Receptor Agonists, Sodium-glucose Cotransport-2 (SGLT-2) Inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, And Meglitinides. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

India Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India Oral Anti-Diabetic Drug Market Size

India Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 1.76 Billion
Market Size (2030) USD 2.09 Billion
CAGR (2025 - 2030) 3.50 %

Major Players

India Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of India Oral Anti-Diabetic Drug Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

India Oral Anti-Diabetic Drug Market Analysis

The India Oral Anti-Diabetic Drug Market size is estimated at USD 1.76 billion in 2025, and is expected to reach USD 2.09 billion by 2030, at a CAGR of 3.5% during the forecast period (2025-2030).

One in six people with diabetes worldwide, according to an article in "THE HINDU," is Indian. With an estimated 80 million diabetics, the country ranks second among the top 10 countries for those with the disease. In India, more than 50% of the population is at risk of developing diabetes at some point in their lives, making it a serious public health issue. Rural parts of India are also experiencing an increase in the incidence of type 2 diabetes. 

After lifestyle changes, oral anti-diabetic medications play a significant role in the management of diabetes. Dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are two novel medications that can be used alone or in combination with existing glucose-lowering medications, such as insulin, when diet and exercise alone are insufficient, and metformin is not tolerated. These drugs have different therapeutic, pharmacokinetic, and safety properties than the more established drugs. 

Recently approved drugs like bromocriptine and hydroxychloroquine (hcq) have positive effects on blood sugar and HbA1C levels. Sulfonylureas (SU) were the only licensed insulin rivals until metformin was approved, and they were widely employed to treat T2DM. While there are now just three SU medications that can be prescribed.

India Oral Anti-Diabetic Drug Industry Overview

India's oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

India Oral Anti-Diabetic Drug Market Leaders

  1. Sanofi

  2. Eli Lilly

  3. Astellas

  4. Janseen

  5. Astrazeneca

  6. *Disclaimer: Major Players sorted in no particular order
India Oral Anti-Diabetic Drug Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

India Oral Anti-Diabetic Drug Market News

  • October 2023: Glenmark Pharmaceuticals has announced the release of a new triple-fixed-dose combination (FDC) medication for diabetes treatment. The company, headquartered in Mumbai, has unveiled the blend of Teneligliptin, Dapagliflozin, and Metformin under the brand name Zita.
  • Jan 2022: Novo Nordisk, the Danish drug maker, announced the launch of oral semaglutide in India for the treatment of type 2 diabetes.
  • Nov 2022: AstraZeneca India gets approval to market anti-diabetes drug. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug Dapagliflozin indicated for diabetes patients with chronic kidney disease (CKD).

India Oral Anti-Diabetic Drug Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028)
    • 5.1.1 Biguanides
    • 5.1.1.1 Metformin
    • 5.1.2 Alpha-Glucosidase Inhibitors
    • 5.1.2.1 Alpha-Glucosidase Inhibitors
    • 5.1.3 Dopamine D2 receptor agonist
    • 5.1.3.1 Bromocriptin
    • 5.1.4 SGLT-2 inhibitors
    • 5.1.4.1 Invokana (Canagliflozin)
    • 5.1.4.2 Jardiance (Empagliflozin)
    • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.4.4 Suglat (Ipragliflozin)
    • 5.1.5 DPP-4 inhibitors
    • 5.1.5.1 Onglyza (Saxagliptin)
    • 5.1.5.2 Tradjenta (Linagliptin)
    • 5.1.5.3 Vipidia/Nesina(Alogliptin)
    • 5.1.5.4 Galvus (Vildagliptin)
    • 5.1.6 Sulfonylureas
    • 5.1.6.1 Sulfonylureas
    • 5.1.7 Meglitinides
    • 5.1.7.1 Meglitinides

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Takeda
    • 7.1.2 Novo Nordisk
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck And Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Novartis
    • 7.1.12 Sanofi
  • *List Not Exhaustive

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

India Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. Diabetes medications are employed to manage diabetes mellitus by reducing the glucose concentration in the bloodstream. Apart from insulin, the majority of GLP receptor agonists (such as liraglutide, exenatide, and others) and pramlintide are taken orally, earning them the name of oral hypoglycemic agents or oral antihyperglycemic agents. India's Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.

Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) Biguanides Metformin
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) Dopamine D2 receptor agonist Bromocriptin
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) SGLT-2 inhibitors Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) DPP-4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) Sulfonylureas Sulfonylureas
Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) Meglitinides Meglitinides
Need A Different Region or Segment?
Customize Now

India Oral Anti-Diabetic Drug Market Research FAQs

How big is the India Oral Anti-Diabetic Drug Market?

The India Oral Anti-Diabetic Drug Market size is expected to reach USD 1.76 billion in 2025 and grow at a CAGR of 3.5% to reach USD 2.09 billion by 2030.

What is the current India Oral Anti-Diabetic Drug Market size?

In 2025, the India Oral Anti-Diabetic Drug Market size is expected to reach USD 1.76 billion.

Who are the key players in India Oral Anti-Diabetic Drug Market?

Sanofi, Eli Lilly, Astellas, Janseen and Astrazeneca are the major companies operating in the India Oral Anti-Diabetic Drug Market.

What years does this India Oral Anti-Diabetic Drug Market cover, and what was the market size in 2024?

In 2024, the India Oral Anti-Diabetic Drug Market size was estimated at USD 1.70 billion. The report covers the India Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the India Oral Anti-Diabetic Drug Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

India Oral Anti-Diabetic Drug Industry Report

Statistics for the 2025 India Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Oral Anti-Diabetic Drug analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.